Liu Xiaomei I, Green Dionna J, van den Anker John N, Rakhmanina Natella Y, Ahmadzia Homa K, Momper Jeremiah D, Park Kyunghun, Burckart Gilbert J, Dallmann André
Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, United States.
Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, United States.
Front Pediatr. 2021 Oct 18;9:723006. doi: 10.3389/fped.2021.723006. eCollection 2021.
While physiologically based pharmacokinetic (PBPK) models generally predict pharmacokinetics in pregnant women successfully, the confidence in predicting fetal pharmacokinetics is limited because many parameters affecting placental drug transfer have not been mechanistically accounted for. The objectives of this study were to implement different maternal and fetal unbound drug fractions in a PBPK framework; to predict fetal pharmacokinetics of eight drugs in the third trimester; and to quantitatively investigate how alterations in various model parameters affect predicted fetal pharmacokinetics. The ordinary differential equations of previously developed pregnancy PBPK models for eight drugs (acyclovir, cefuroxime, diazepam, dolutegravir, emtricitabine, metronidazole, ondansetron, and raltegravir) were amended to account for different unbound drug fractions in mother and fetus. Local sensitivity analyses were conducted for various parameters relevant to placental drug transfer, including influx/efflux transfer clearances across the apical and basolateral membrane of the trophoblasts. For the highly-protein bound drugs diazepam, dolutegravir and ondansetron, the lower fraction unbound in the fetus vs. mother affected predicted pharmacokinetics in the umbilical vein by ≥10%. Metronidazole displayed blood flow-limited distribution across the placenta. For all drugs, umbilical vein concentrations were highly sensitive to changes in the apical influx/efflux transfer clearance ratio. Additionally, transfer clearance across the basolateral membrane was a critical parameter for cefuroxime and ondansetron. In healthy pregnancies, differential protein binding characteristics in mother and fetus give rise to minor differences in maternal-fetal drug exposure. Further studies are needed to differentiate passive and active transfer processes across the apical and basolateral trophoblast membrane.
虽然基于生理的药代动力学(PBPK)模型通常能成功预测孕妇的药代动力学,但由于许多影响胎盘药物转运的参数尚未从机制上进行考虑,因此预测胎儿药代动力学的可信度有限。本研究的目的是在PBPK框架中纳入不同的母体和胎儿游离药物分数;预测孕晚期8种药物的胎儿药代动力学;并定量研究各种模型参数的变化如何影响预测的胎儿药代动力学。对先前开发的8种药物(阿昔洛韦、头孢呋辛、地西泮、多替拉韦、恩曲他滨、甲硝唑、昂丹司琼和拉替拉韦)的妊娠PBPK模型的常微分方程进行了修正,以考虑母体和胎儿中不同的游离药物分数。对与胎盘药物转运相关的各种参数进行了局部敏感性分析,包括跨滋养层顶端和基底外侧膜的流入/流出转运清除率。对于高蛋白结合药物地西泮、多替拉韦和昂丹司琼,胎儿与母体中较低的游离分数使脐静脉中预测的药代动力学受到≥10%的影响。甲硝唑在胎盘的分布受血流限制。对于所有药物,脐静脉浓度对顶端流入/流出转运清除率的变化高度敏感。此外,跨基底外侧膜的转运清除率是头孢呋辛和昂丹司琼的关键参数。在健康妊娠中,母体和胎儿不同的蛋白结合特性导致母胎药物暴露存在微小差异。需要进一步研究以区分跨滋养层顶端和基底外侧膜的被动和主动转运过程。